Insider Selling: Edward O. Lanphier II Unloads 50,000 Shares of Sangamo BioSciences Stock (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) CEO Edward O. Lanphier II unloaded 50,000 shares of the stock on the open market in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $18.09, for a total value of $904,500.00. Following the sale, the chief executive officer now directly owns 295,000 shares of the company’s stock, valued at approximately $5,336,550. The transaction was disclosed in a filing with the SEC, which is available at this link.
Sangamo BioSciences (NASDAQ:SGMO) traded down 0.49% on Wednesday, hitting $18.27. The stock had a trading volume of 588,415 shares. Sangamo BioSciences has a 52-week low of $6.86 and a 52-week high of $20.74. The stock has a 50-day moving average of $18.13 and a 200-day moving average of $12.75. The company’s market cap is $1.129 billion.
Sangamo BioSciences (NASDAQ:SGMO) last released its earnings data on Tuesday, February 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.03. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $8.90 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was down 22.5% on a year-over-year basis. Analysts expect that Sangamo BioSciences will post $-0.43 EPS for the current fiscal year.
Separately, analysts at Wedbush raised their price target on shares of Sangamo BioSciences to $22.00 in a research note on Thursday, January 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Sangamo BioSciences currently has an average rating of “Buy” and a consensus price target of $18.75.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.